Read our latest updates & insights

On 12 August 2024, Xbrane reported that it has commenced processes to out-license Xdivane™, biosimilar to BMS’ Opdivo® (nivolumab), and XB003 (previously known as Xcimzane™, BIIB801), biosimilar to UCB’s Cimzia® (certolizumab pegol).  The out-licensing process is to ensure ...

On 9 August 2024, Sandoz announced its Q2 2024 sales and financial results for half year ended 30 June 2024, reporting net sales of USD 2.6 billion for Q2/24, an increase of 9% when compared to the same quarter in 2023.  Net sales for biosimilars in the same period were USD...

On 9 August 2024, Celltrion announced that its Zymfentra™  (infliximab-dyyb) has been included in 26 US formularies, including for 3 major Prescription Benefit Managers (PBMs), just five months after launch.  According to Celltrion, the formulary listings provide 75% of cov...

On 9 August 2024, New Zealand’s Pharmaceutical Medicines Agency (Pharmac) announced that it is seeking commercial bids from suppliers for the supply of bevacizumab for a range of cancers.

Bevacizumab is currently funded in NZ hospitals for recurrent respiratory papil...

On 9 August 2024, MSD and Curon Biopharmaceutical announced the MSD acquisition of Curon developed CD3xCD19 bispecific antibody CN201, currently in Ph I/II trials for the treatment of B-cell associated diseases.  Under the agreement, MSD will make an upfront payment of $700...

Ono Pharmaceutical and Bristol-Myers Squibb have announced a supplemental application in Japan for Ono’s Opdivo® and BMS’s Yervoy® in combination therapy, to expand its approved use to the treatment of unresectable hepatocellular carcinoma (HCC).

Ono’s 2011 grant to ...

On 8 August 2024, Biocon Limited reported year on year consolidated revenue growth of 30% for Q2 2024, primarily as a result of a “one-time gain” from the strategic collaboration between Biocon and Eris Lifesciences announced in March 2024.  Although revenue for Biocon’s ge...

Fresenius Kabi has walked away from the Australian adalimumab market and cancelled its approvals for 40mg Idacio® pre-filled syringe and 40mg Idacio® pen products which were approved as biosimilars to AbbVie’s Humira®.  The withdrawals are listed on the TGA Medicines Shorta...

On 7 August 2024, Novo Nordisk released its financial report which showed a strong increase in profits in the first half of 2024.  Novo Nordisk’s total sales equalled DKK 133.4 billion in the first six months of 2024, an increase of 24% in DKK and 25% when measured ac...

Chugai announced that it has concluded a license agreement with Roche for Roche’s pipeline product RG6631, an anti-TL1A antibody, in late-stage product development for ulcerative colitis and Crohn’s disease.  Under the agreement, Chugai, which is 62% owned by Roche, obtains...